NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) ("Prospect", the "Company", "our", or "we") today announced that it held its special meeting of stockholders (the "Special Meeting") on June 23, 2026. The proposal that was considered at the Special Meeting is described in detail in the Company’s definitive proxy statement for the Special Meeting as filed with the Securities and Exchange Commission on March 11, 2026 (the "Proxy"). As of March 11, 2026, there were 486,484,945 shares of the Company's common stock outstanding, 25,394,532 shares of the Company’s 5.50% Series A1 Preferred Stock outstanding (the "Series A1 Preferred Stock"), 163,000 shares of
Live Feed
Delayed 3mPress · Analyst · Insider · Buys · FDA
Signed out · 3-min delay · Sign up for real-time
- Prospect Capital Announces Special Meeting Update
- SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- Director Stovsky Richard P was granted 2,144 shares, increasing direct ownership by 8% to 29,562 units (SEC Form 4)
4 - ENCORE CAPITAL GROUP INC (0001084961) (Issuer)
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 924 shares, decreasing direct ownership by 0.30% to 310,623 units (SEC Form 4) to cover taxes
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- Director Barker Thorold was granted 16 units of 2025 Annual Restricted Stock Units, increasing direct ownership by 0.97% to 1,665 units (SEC Form 4)
4 - Moelis & Co (0001596967) (Issuer)
- Director Olle Laura was granted 2,144 shares, increasing direct ownership by 6% to 37,168 units (SEC Form 4)
4 - ENCORE CAPITAL GROUP INC (0001084961) (Issuer)
- Chief Executive Officer Eberwein Jeffrey E. bought $55,765 worth of Common Stock. (5,000 units at $11.15), increasing direct ownership by 0.45% to 1,115,714 units (SEC Form 4)
4 - Star Equity Holdings, Inc. (0001210708) (Issuer)
- Director Shropshire Kenneth was granted 21 units of 2024 Annual Restricted Stock Units, was granted 18 units of 2025 Annual Restricted Stock Units and was granted 1 units of 2025 Elective Restricted Stock Units, decreasing direct ownership by 98% to 54 units (SEC Form 4)
4 - Moelis & Co (0001596967) (Issuer)
- Director Monaco Michael P was granted 2,144 shares, increasing direct ownership by 5% to 42,256 units (SEC Form 4)
4 - ENCORE CAPITAL GROUP INC (0001084961) (Issuer)
- Director Worrell Laila was granted 20 units of 2024 Annual Restricted Stock Units, was granted 17 units of 2025 Annual Restricted Stock Units and was granted 5 units of 2025 Elective Restricted Stock Units, decreasing direct ownership by 77% to 480 units (SEC Form 4)
4 - Moelis & Co (0001596967) (Issuer)
- SEC Form 4 filed by Vice Chairman, MD Cantor Eric
4 - Moelis & Co (0001596967) (Issuer)
- Director Angela A. Knight was granted 2,144 shares, increasing direct ownership by 9% to 26,475 units (SEC Form 4)
4 - ENCORE CAPITAL GROUP INC (0001084961) (Issuer)
- SEC Form 4 filed by General Counsel, Secretary Watanabe Osamu R.
4 - Moelis & Co (0001596967) (Issuer)
- SEC Form 4 filed by Principal Accounting Officer Riehl Nick
4 - Moelis & Co (0001596967) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Pilcher Ciafone Katherine
4 - Moelis & Co (0001596967) (Issuer)
- Director Hilzinger Jeffrey Albert was granted 2,144 shares, increasing direct ownership by 9% to 26,475 units (SEC Form 4)
4 - ENCORE CAPITAL GROUP INC (0001084961) (Issuer)
- SVP, DEV & HEAD OF IRE OFFICE Miller Aine was granted 18,750 units of Ordinary Shares, increasing direct ownership by 11% to 196,084 units (SEC Form 4)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)